Inhibition of fibrin-bound thrombin by a covalent antithrombin-heparin complex

Journal of Biochemistry

Volumn 132, Issue 2, 2002, Pages 167-176

  Berry, Leslie R ^a   Becker, Debra L ^b   Chan, Anthony K C ^a  

^a HENDERSON RESEARCH CENTRE   (Canada)

^b Innous Research   (Canada)

Author keywords

Antithrombin heparin; Fibrin; Heparin; Rate; Thrombin

Indexed keywords

ANTITHROMBIN; FIBRIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MONOMER; BLOOD CLOTTING FACTOR 10A; FIBRONECTIN; THROMBIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL REACTION KINETICS; COMPLEX FORMATION; ELECTROPHORESIS; ENZYME INHIBITION; PROTEIN BINDING; PROTEIN DENATURATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; HUMAN; MACROMOLECULE; METABOLISM; SPECTROFLUOROMETRY; SWINE;

ANIMALS; ANTITHROMBINS; BINDING SITES; FACTOR XA; FIBRIN; FIBRONECTINS; HEPARIN; HUMANS; MACROMOLECULAR SUBSTANCES; PROTEIN BINDING; SPECTROMETRY, FLUORESCENCE; SWINE; THROMBIN;

EID: 0036684179     PISSN: 0021924X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.jbchem.a003206     Document Type: Article

References (56)

1. The purification and mechanism of action of human antithrombin-heparin cofactor
2. Identification of two distinct heparin cofactors in human plasma. II. Inhibition of thrombin and activated factor X
3. Demonstration of a two-step reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin
4. Molecular mechanisms of the accelerating effect of heparin on the reactions between anti-thrombin and clotting proteinases
5. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti factor Xa activity
6. The chemistry of heparin: A way to understand its mode of action
7. Binding of heparin to antithrombin III: A chemical proof of the critical role played by a 3-sulfated 2-amino-2-deoxy-D-glucose residue
8. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement
9. Role of tryptophan 49 in the heparin cofactor activity of human antithrombin III
10. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin
11. The anticoagulant activation of antithrombin by heparin
12. 2-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis
13. Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta
14. Mechanism of thrombin inactivation by immobilized heparin
15. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma
16. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
17. Selective immobilization of thrombin by surface bound fibrin
18. Thrombin interaction with fibrin polymerization sites
19. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
20. Dermatan sulphate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins
21. Thrombin specificity
22. Intrinsic fluorescence changes and rapid kinetics of the reaction of thrombin with hirudin
23. Formation of a ternary complex between thrombin, fibrin monomer, and heparin influences the action of thrombin on its substrates
24. Binding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin and inhibits cleavage of fibrinogen
25. Modulation of thrombin and heparin activities by fibrin
26. Heparin promotes the binding of thrombin to fibrin polymer. Quantitative characterization of a thrombin-fibrin polymer-heparin ternary complex
27. Covalent antithrombin-heparin complexes with high anticoagulant activity: Intravenous, subcutaneous and intratracheal administration
28. Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex
29. Effect of a novel covalent antithrombin-heparin complex on thrombin generation on fetal distal lung epithelium
30. A novel antithrombin-heparin covalent complex: Antithrombotic and bleeding studies in rabbits
31. Plasminogen activator activity in preterm infants with respiratory distress syndrome: Relationship to the development of bronchopulmonary dysplasia
32. Pathways of fibrin turnover in lavage of premature baboons with hypoxic lung injury
33. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress sydrome
34. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome
35. Leakage of protein into lungs of preterm ventilated rabbits is correlated with activation of clotting, complement, and polymorphonuclear leukocytes in plasma
36. Glycosaminoglycan contributions to both protein C activation and thrombin inhibition involve a common arginine-rich site in thrombin that includes residues arginine 93, 97, and 101
37. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate
38. Polypeptide-polysaccharide conjugates produced by spontaneous non-enzymatic glycation
39. Phospholipid-binding properties of bovine factor V and factor Va
40. Regulation of formation of factor XIIIa by its fibrin substrates
41. Amino acids and peptides. XVI. Synthesis of N-terminal tetrapeptide analogs of fibrin alpha-chain and their inhibitory effects on fibrinogen/thrombin clotting
42. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin
43. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
44. Heparin and low molecular weight heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
45. Control mechanisms in thrombin generation
46. Activation of human blood coagulation factor XI independent of factor XII: Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces
47. Factor XI activation in a revised model of blood coagulation
48. Importance of factor Xa in determining the procoagulant activity of whole-blood clots
49. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots
50. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors
51. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II
52. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa
53. Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization of the factor Xa binding site on fibrinogen
54. Importance of factor Xa in determining the procoagulant activity of whole blood clots
55. Interaction of heparin with fibrinogen using surface plasmon resonance technology: Investigation of heparin binding site on fibrinogen
56. Heparin-binding domain of fibrin mediates its binding to endothelial cells